HMP Market Access Insights

In part 3 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—conclude their conversation on oncology practice economics, discussing emerging models for success (e.g., utilization of advanced therapies) and manufacturer implications.

In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—continue their exploration of oncology practice economics, focusing on practices’ operational realities.

In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider. and oncology strategist—explore the current state of oncology practice economics.

 In part 2 of this 2-part podcast series, HMP MAI Director of Payer Insights Chris Van Denburg and special guest Tina Valbh – pharmacist and oncology patient – continue their exploration of oncology patient support services programs, with several key pieces of advice for biopharmaceutical companies.

In part 1 of this 2-part podcast series, HMP MAI Director of Payer Insights Chris Van Denburg and special guest Tina Valbh – pharmacist and oncology patient – explore her experiences with and advice for oncology patient support services programs, emphasizing those provided by biopharmaceutical companies.

HMP MAI Director of Payer Insights Chris Van Denburg and special guest and notable specialist Carole Tremonti, RN, MBA, investigate key insights about what clinical decision support systems—and AI—are and are NOT, what we can rely on them for currently, and how biopharmaceutical companies with oncology products can prepare for success related to these advances. 

In this episode, you will hear from the research leads for each of our key customer segments about 3 notable quotes they heard from conversations this year with providers, payers, and administrators in the oncology sector.

In this episode, we provide highlights on key insights from our 2023 Community Oncology Annual Trend Report, including why it's important for pharma companies to tailor their approach with community oncology groups based on what archetype they fall under. 

Part 2 of HMP MAI’s podcast on value-based cancer care looking at how prevalent VBC is in primary and cancer care, private payer VBC activity specifically in oncology, and ideas about how biopharmaceutical manufacturers might adjust to shifting customer interests because of VBC.

Part 1 of HMP MAI’s podcast on value-based cancer care looking at traditional provider priorities, how VBC attempts to adjust those priorities, and who some of the largest VBC players are in primary and cancer care.